TABLE 2.

Epigenetic drugs for radiotherapy enhancement.

Drugs	Target	Phase	Application	Results	References
Panobinostat	HDACi	I	High-grade gliomas	Three grade 3 toxicities, one grade 4 neutropenia in 12 patients.	Shi et al., 2016
Vorinostat	HDACi	I	Gastrointestinal carcinoma	Seven grade 3 adverse events in 16 patients.	Ree et al., 2010
Vorinostat	HDACi	I/II	Glioblastoma	Shorter PFS and OS associated with high scores for the signature sig-79; conversely, patients with high scores on the sig-139 had longer PFS and OS.	Galanis et al., 2018
Belinostat	Pan-HDACi	II	Glioblastoma	Stable disease for 16 months and consistent improvement in neurocognition over 18 months.	Gurbani et al., 2020
Valproic acid	HDACi	Retrospective	Glioblastoma	Improvements in PFS (median 22.7 vs. 11.0 months; P = 0.099; HR, 0.62), in OS (median 42.2 vs. 20.3 months; P < 0.01; HR, 0.36).	Watanabe et al., 2017